GLS and cancer: Extensive testing has demonstrated its efficacy in inhibiting growth across various cancer cell types.[20, 48] Instead of targeting GLS, a glutamine antagonist named 6‐diazo‐5‐oxo‐L‐norleucine (DON) has also been investigated.